Table of Contents
Key Point
- Kenneth Frazier’s stake in Merck dropped $4.72 million, falling below $90 million.
- Merck & Co’s stock falls 5.03% on the NYSE, reducing its market cap below $320 billion.
- Despite recent losses, Merck shares are up 15.82% YTD in 2024, turning a $100,000 investment into $115,820.
Kenneth Frazier, the pioneering Black executive and former CEO and executive chairman of Merck & Co., has encountered a significant financial setback as the market value of his stake in the pharmaceutical giant dropped below $90 million.
According to data gathered by Billionaires.Africa, Kenneth Frazier’s shareholding in Merck & Co. has decreased by $4.72 million over the past twenty-five days. This decline follows a period when his holding rebounded above $90 million between May 30 and June 24, from $87.82 million to $92.18 million.
Merck shares drop 5.03%, market cap falls below $320 billion
Merck remains a top player in the pharmaceutical industry, offering a diverse portfolio of prescription drugs, vaccines, biological therapies, animal health products, and consumer healthcare solutions. The company operates through three segments: pharmaceutical, animal health, and other segments.
Merck’s share price on the New York Stock Exchange has slumped by 5.03 percent over the past twenty-five days, dropping from $132.96 on June 24 to $126.27 at the time of writing. This decline has pushed the company’s market capitalization below $320 billion, resulting in significant losses for investors.
Frazier’s Merck stake dips $4.7 million amid market slump
Frazier, a prominent figure among America’s top Black executives, owns a 0.028-percent stake in Merck & Co., equivalent to 705,220 shares, valued at $89 million.
As a result of the recent single-digit percentage slump in the pharmaceutical group’s shares, the market value of Kenneth Frazier’s stake declined from $93.77 million on June 24 to $89.05 million, marking a $4.72 million reduction over 25 days. Despite this decline, Frazier remains a high-value investor on the NYSE.
Your Money and Your Life
Merck & Co., a leading pharmaceutical giant, has delivered substantial gains to investors since the start of the year. Its shares on the NYSE have surged by 15.82 percent year-to-date in 2024.
A $100,000 investment in Merck at the start of the year would now be valued at $115,820, reflecting a gain of $15,820.
The intelligence satisfies curiosity. The paid briefings satisfy strategy.
Every Monday, Elite subscribers receive an Investor Memo breaking down the deal, the structure and the positioning behind the week's most consequential African wealth story - the kind of analysis that doesn't appear anywhere else.
Twice a month, a Wealth Intelligence brief profiles a single billionaire's holdings, cash flows and expansion pipeline in detail no public source matches.
→ Executive ($25/mo): Daily newsletter + Deep-Dive Reports
→ Elite ($75/mo): Everything above + Investor Memos + Wealth Intelligence + Quarterly Analyst Briefings
Subscribe now
